Concord Biotech has secured USFDA approval for its Mycophenolate Mofetil for Oral Suspension USP, marking a key regulatory milestone for the company.
Updates Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'. Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'.
Updates Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'. Concord Biotech Limited has informed the Exchange regarding Abbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL'.
Company Update We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Company Update We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. We are pleased to inform that the Company has received approval from USFDA for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Investor Presentation Concord Biotech Limited has informed the Exchange about Investor Presentation Concord Biotech Limited has informed the Exchange about Investor Presentation
Outcome of Board Meeting Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome of Board Meeting Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Corp. Action The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26. The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.
Corp. Action The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26. The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.
Corp. Action The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26. The Board has recommended dividend of Rs. 7.55 per equity share of face value of Rs. 1 each fully paid up for the Financial Year 2025-26.
Dividend Concord Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 7.55 per equity share. Concord Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 7.55 per equity share.
NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.